Axicabtagene Ciloleucel (NCT06043323)

Name: Axicabtagene Ciloleucel trial for Follicular Lymphoma (NCT06043323)
Uploaded: 2026-10-31T19:45:13.501Z
Duration: 1 min 10 s
Description: Axicabtagene Ciloleucel trial for Follicular Lymphoma (NCT06043323). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06043323.

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma: a one-minute explainerNCT060433231 min

Axicabtagene Ciloleucel trial for Follicular Lymphoma (NCT06043323). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with grade 1–3A follicular lymphoma that returned or resisted at least two prior systemic treatments, and who can receive CAR T-cell therapy.

The idea: collected white blood cells are modified to target CD19. Patients receive radiation, conditioning chemotherapy, then one intravenous axicabtagene ciloleucel infusion. Researchers test the safety of this sequence and assess lymphoma response. Urgent bridging chemotherapy excludes participation.

This phase 2 study plans 20 patients. Susan Wu leads at MD Anderson in Houston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.